Drug Trial Radar · NCT07253584
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia
Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
720
Actual
Start
Dec 19, 2023
Primary completion
Jun 23, 2025
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Recombinant Fully Human Anti-PCSK9 Monoclonal Antibody Injection (SAL003) in Combination with Statin Therapy in Patients with Hypercholesterolemia and Mixed Dyslipidemia.
Conditions
- Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia
Interventions
SAL003 140 mgDrug
SAL003 140 mg
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change of LDL-CTime frame: at Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Xi 'an Jiaotong University
Xi’an, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.